Dr. Hanmei Lou 楼寒梅
Chief Physician
Department of Gynecologic Oncology, Zhejiang Cancer Hospital, Hangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of benign and malignant gynecologic tumors, including surgery and comprehensive care for cervical, endometrial, vulvar, and ovarian cancers. Clinical application of sentinel lymph node detection for early cervical cancer.
Dr. Lou is Chief Physician and Deputy Director of the Gynecologic Oncology Radiotherapy Ward at Zhejiang Cancer Hospital. Graduating from Zhejiang Medical University in 1992, Dr. Lou earned a master’s degree from Zhejiang University School of Medicine in 2006. Selected for Zhejiang Province’s "New Century 151 Talent Project" in 2009, Dr. Lou has authored over 10 papers and co-edited four monographs.
Name order: in Chinese the family name comes first (Lou Hanmei). Papers usually list the name as Hanmei Lou or Lou H.
Selected publications
43 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Cell Rep Med, 2026 (first author): Iparomlimab and tuvonralimab in previously treated patients with cervical cancer. PubMed 42551432
- Elife, 2025 (senior author): Monitoring circulating cell-free HPV DNA in metastatic or recurrent cervical cancer: clinical significance and treatment implications. PubMed 40960177
- J Gynecol Oncol, 2025 (senior author): Efficacy and safety of cisplatin combined with paclitaxel concurrent radiotherapy in patients with locally advanced cervical squamous cell carcinoma. PubMed 39900342
- Front Immunol, 2024 (senior author): Second-line monotherapy with a PD-1/CTLA-4 inhibitor effectively treated multiple brain and lung metastases of cervical cancer: a case report. PubMed 39469707
- Clin Cancer Res, 2024 (first author): Cadonilimab Combined with Chemotherapy with or without Bevacizumab as First-Line Treatment in Recurrent or Metastatic Cervical Cancer (COMPASSION-13): A Phase 2 Study. PubMed 38372727
- J Med Virol, 2023 (senior author): HPV-related cervical diseases: Alteration of vaginal microbiotas and promising potential for diagnosis. PubMed 36437385
- Radiat Oncol, 2022 (senior author): Whether individualized dose escalation should be recommended for lymph nodes with different sizes in the definitive radiotherapy of cervical cancer?. PubMed 36266716
- BMC Cancer, 2020 (senior author): Comparison of adenocarcinoma and adenosquamous carcinoma prognoses in Chinese patients with FIGO stage IB-IIA cervical cancer following radical surgery. PubMed 32678039
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion